A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3000202 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3000202 as Tablet With and Without Food in Healthy Male Subjects
Latest Information Update: 04 Dec 2023
At a glance
- Drugs BI 3000202 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 29 Nov 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2023 Status changed from not yet recruiting to recruiting.